Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
B01AC24 - TicagrelorATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
B01 - Antithrombotic Agents
B01A - Antithrombotic Agents
B01AC - Platelet Aggregation Inhibitors Excl. Heparin

Acetylsalicylic acid preparations specifically intended for use as antithrombotic agents are classified in this group. This exception from the basic principle of only one code for each route of administration is made because of the extensive use of acetylsalicylic acid both as an antithrombotic agent and as an analgesic. Whether an acetylsalicylic acid product should be classified in this group or in N02BA, should be decided at the national level based on the main indication of the product.
Lysine acetylsalicylate is classified at the same 5th level as acetylsalicylic acid.
Sulfinpyrazone is classified in M04AB. Alprostadil is classified in C01EA and G04BE.
Combinations of acetylsalicylic acid and rivaroxaban are classified in B01AF.
Combinations of acetylsalicylic acid and statins are classified in C10BX.
Combinations of acetylsalicylic acid, ACE inhibitors and statins are classified in C10BX.
Combinations of acetylsalicylic acid and beta blocking agents are classified in C07FX.
Prostaglandines are classified in this group while other agents used for pulmonary arterial hypertension are classified in C02KX or in G04BE.

The DDDs are based on prophylaxis of thrombosis. The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength. This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.
The DDD of iloprost is based on treatment of peripheral vascular disease.
The DDD of vorapaxar is based on the content of one tablet (2.08 mg).
The DDD of selexipag is based on treatment of pulmonary arterial hypertension.
For combinations products, see list of DDDs for combinations,

B01AC24 - Ticagrelor
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home